Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal… Read More
Finance Manager Company name: ONA Therapeutics Job location: Barcelona, Catalonia, Spain (Hybrid) Company Description Ona Therapeutics is a biotech company located in Barcelona (Parc Científic de Barcelona, PCB), focused on developing first-in-class antibody drug conjugates (ADCs) for advanced cancer treatment. By partnering with leading… Read More
Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its… Read More
We are developing ADC therapies for tough-to-treat cancers by unlocking a deeper understanding of drug-resistant tumor biology. 💊 “With cutting-edge research, world-class clinical expertise, and a surge in biotech investment, Barcelona’s next masterpiece could be a first-in-class medicine.” 🚀 Proud to be part of Barcelona’s booming biotech scene… Read More
At ONA Therapeutics we are priviledged to collaborate with top-tier Spanish hospitals to bring our first-in-class ADCs to cancer patients. 🔝 Valerie Vanhooren, CEO and co-founder of ONA Therapeutics is featured in the latest… Read More
Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with… Read More
Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Dr. Pamela Klein is a medical oncologist and seasoned… Read More
Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors. Dr Michel Detheux is a veteran biotech executive… Read More
CataloniaBio & HealthTech has recognised ONA Therapeutics with the Biosuccess award 2021 for its consolidation, investment attraction and growth as a spin-off. The event took place during the UnConference, the annual day of debate on the future of healthcare solutions promoted by CataloniaBio & HealthTech. ONA Therapeutics S.L. is a… Read More